Yun Xie

Dr. Yun Xie


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZZZhigang Zhou
Zhigang Zhou
TFtienan feng
tienan feng
YXYun Xie
Yun Xie
PHPeijie Huang
Peijie Huang
HXHui Xie
Hui Xie
RWRuilan Wang
Ruilan Wang
Sepsis is still a common critical disease with high morbidity and mortality in intensive care unit. Despite published guidelines for sepsis, development of antibiotic therapy and advanced organ support technologies, the mortality of sepsis patients is still 25% or more. It is necessary to distinguish the subtypes of sepsis, and the targeted therapy for the patients need to be explored. Platelets have various biological functions in hemostasis and thrombosis, host defense, inflammatory/immune responses and tissue repair/regeneration. Moreover, severe thrombocytopenia or sustained thrombocytopenia was closely associated with multiply organ dysfunction and higher mortality in sepsis patients. The clinical therapies for thrombocytopenia are platelet transfusion and platelet-elevating drugs. However, platelet transfusion has many defects in clinical practice in sepsis patients, and the impact of platelet-elevating drugs for sepsis patients is still unclear. RESCUE trial is aim to explore the effect of a platelet-elevating drug, recombinant human thrombopoietin (rhTPO), as an effective rescue therapy on sepsis patients with acute severe thrombocytopenia. It is a randomized, open-label, multi-center, controlled trial in 5 tertiary academic hospitals including medical, surgical or general ICUs. In this study, a total of 200 sepsis patients with severe thrombocytopenia will be randomly assigned in a 1:1 ratio to the control and rhTPO group. The patients will be followed up to 28 days after randomization. All patients in two groups receive the same treatment based on the guideline of Surviving Sepsis Campaign. Primary outcome is 28-day mortality. Secondary outcomes are the changes of PCs, blood transfusion, biomarkers of infection and organ function, days free from advanced organ support, drug-related adverse events, the length of ICU and hospital stay. RESCUE trial is the first randomized controlled trial to explore the impact of rhTPO for severe thrombocytopenia in sepsis patients diagnosed by sepsis-3.0 standard. Furthermore, RESCUE trial results will be of significant clinical value on the targeted therapy and add clinical evidence that rhTPO is an effective rescue therapy for these sepsis patients. ClinicalTrials.gov : NCT02707497. Registered Date: March 3rd, 2016. Protocol Version 3. Protocol Date: January 25th, 2019.


7 July 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
DCDaonan Chen
Daonan Chen
HXHui Xie
Hui Xie
PHPeijie Huang
Peijie Huang
RWRuilan Wang
Ruilan Wang
YXYun Xie
Yun Xie
Sepsis-induced myocardial injury (SIMI) is a common and severe complication of sepsis associated with increased mortality, yet its underlying mechanisms are not fully elucidated. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation and oxidative stress, has been implicated in preclinical models of septic cardiomyopathy. However, clinical evidence in humans remains limited, and the specificity of related biomarkers requires careful interpretation. This prospective observational study enrolled 180 ICU-admitted sepsis patients (91 with SIMI and 89 without) from January to June 2025. Serum ferroptosis-related biomarkers, including malondialdehyde (MDA), lipid peroxidation (LPO), glutathione (GSH), reactive oxygen species (ROS), and ferrous iron (Fe²⁺), were measured at 24 h post-admission. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves, and independent predictors were identified via multivariable logistic regression adjusting for clinical confounders. Compared with the non-SIMI group, SIMI patients showed significantly altered ferroptosis-related markers (all P < 0.001): higher MDA [6.08 (5.38-6.67) vs. 4.47 (3.92-5.30) nmol/mL], LPO, ROS, and Fe²⁺, and lower GSH. ROC analysis demonstrated moderate-to-good diagnostic discrimination for SIMI (AUC 0.746-0.825), with Fe²⁺ showing the highest AUC (0.825), followed by ROS (0.793) and MDA (0.787); these outperformed BNP but were inferior to cTnI. Multivariable logistic regression identified Fe²⁺ (OR = 11.883, P < 0.001) as the only independent ferroptosis-related predictor of SIMI, alongside cTnI and APACHE II score. The full model exhibited excellent discrimination (AUC = 0.989) and good calibration (Hosmer-Lemeshow P = 0.935). Elevated ferroptosis-related biomarkers reflecting systemic oxidative stress and iron dysregulation are significantly associated with SIMI, with Fe²⁺ emerging as an independent predictor. These biomarkers provide additive diagnostic value beyond traditional cardiac markers but are not specific for ferroptosis as a regulated cell death mechanism and likely represent broader redox imbalance in severe sepsis. These findings support further investigation into iron-targeted and oxidative stress-modulating strategies in septic cardiac dysfunction.

19 March 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
QDQunzhe Ding
Qunzhe Ding
YZYi Zhang
Yi Zhang
ZZZihao Zhang
Zihao Zhang
PHPeijie Huang
Peijie Huang
RTRui Tian
Rui Tian
YXYun Xie
Yun Xie
Background: Pneumonia is a leading cause of morbidity and mortality among patients with cancer, and survival time is a primary concern. Despite their importance, there is a dearth of accurate predictive models in clinical settings. This study aimed to determine the incidence of pneumonia as a cause of death in patients with cancer, analyze trends and risk factors associated with mortality, and develop corresponding predictive models.Methods: We included 26,938 cancer patients in the United States who died from pneumonia between 1973 and 2020, as identified through the Surveillance, Epidemiology, and End Results (SEER) program. Cox regression analysis was used to ascertain the prognostic factors for patients with cancer. The CatBoost model was constructed to predict survival rates via a cross-validation method. Additionally, our model was validated using a cohort of cancer patients from our institution and deployed via a free-access software interface.Results: The most common cancers resulting in pneumonia-related deaths were prostate (n=7300) and breast (n=5107) cancers, followed by lung and bronchus (n=2839) cancers. The top four cancer systems were digestive (n=5882), endocrine (n=5242), urologic (n=5198), and hematologic (n=3104) systems. The majority of patients were over 70 years old (57.7%), and 54.4% were male. Our CatBoost model demonstrated high precision and accuracy, outperforming other models in predicting the survival of cancer patients with pneumonia (6-month AUC=0.8384,1-year AUC=0.8255,2-year AUC=0.8039, and 3-year AUC=0.7939). The models also revealed robust performance in an external independent dataset (6-month AUC=0.689; 1-year AUC=0.838; 2-year AUC=0.834; and 3-year AUC=0.828). According to the SHAP explanation analysis, the top five factors affecting prognosis were surgery, stage, age, site, and sex; surgery was the most significant factor in both the short-term (6 months and 1 year) and long-term (2 years and 3 years) prognostic models; surgery improved patient prognosis for digestive and endocrine tumor sites with respect to both short- and long-term outcomes but decreased the prognosis of urological and hematologic tumors.Conclusion: Pneumonia remains a major cause of illness and death in patients with cancer, particularly those with digestive system cancers. The early identification of risk factors and timely intervention may help mitigate the negative impact on patients’ quality of life and prognosis, improve outcomes, and prevent early deaths caused by infections, which are often preventable.


27 February 2025 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
QDQun-Zhe Ding
Qun-Zhe Ding
RWRui-Lan Wang
Rui-Lan Wang
YXYun Xie
Yun Xie
We discuss the findings of Wu et al on the utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammatory index as diagnostic markers for gastric carcinoma (GC). We commend the study's contributions to the field and suggest a prospective study to validate these markers' sensitivity and specificity for early GC detection. We also propose developing surveillance protocols that incorporate these markers with other diagnostic methods to enhance clinical decision-making. Furthermore, we highlight the need for a more diverse patient cohort to assess the generalizability of these markers across different ethnic groups and demographic factors. Our suggestions aim to refine the application of these markers in clinical practice and to understand their potential in diverse clinical scenarios.